Core Viewpoint - On September 2, Xiaofang Pharmaceutical experienced a decline of 1.26% in stock price, with a trading volume of 93.99 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On the same day, Xiaofang Pharmaceutical had a financing buy-in amount of 17.32 million yuan, with a financing repayment of 9.77 million yuan, resulting in a net financing buy-in of 7.55 million yuan [1]. - As of September 2, the total financing and securities lending balance for Xiaofang Pharmaceutical reached 126 million yuan, with the current financing balance accounting for 6.73% of the circulating market value [1]. Company Overview - Xiaofang Pharmaceutical, established on August 12, 1993, is located in Shanghai and specializes in the research, production, and sales of external-use medications [1]. - The company's revenue composition is as follows: digestive medications 51.05%, skin medications 39.79%, otorhinolaryngology medications 9.08%, and others 0.07% [1]. Financial Performance - For the first half of 2025, Xiaofang Pharmaceutical reported a revenue of 270 million yuan, reflecting a year-on-year growth of 3.06%, while the net profit attributable to shareholders was 121 million yuan, showing a growth of 1.69% [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xiaofang Pharmaceutical was 14,800, a decrease of 22.41% from the previous period, while the average circulating shares per person increased by 28.88% to 2,703 shares [1]. - The company has distributed a total of 241 million yuan in dividends since its A-share listing [2]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, CITIC Jiantou Rotation Mixed A (003822) ranked as the third-largest shareholder with 439,400 shares, being a new shareholder [2]. - CITIC Jiantou Selection Mixed A (008347) was the fourth-largest shareholder with 298,100 shares, also a new addition, while Taixin First Strategy Mixed (290002) remained the fifth-largest shareholder with 256,800 shares, unchanged from the previous period [2].
小方制药9月2日获融资买入1732.30万元，融资余额1.26亿元